FNHTR is the most common transfusion reaction, occurring in approximately 1% of transfusion episodes (1–3% per unit transfused). [1] It is a diagnosis of exclusion — defined by a temperature rise of ≥1°C during or shortly after transfusion, after ruling out hemolysis, sepsis, and other transfusion-related complications. [1-2] The pathophysiology involves pro-inflammatory cytokines accumulated in stored blood products and/or recipient antibodies reacting against donor leukocyte antigens. [1][3]
1. History
- Onset of fever (≥38°C or rise ≥1°C from baseline) during or within 1–4 hours of transfusion [1]
- Associated chills, rigors (14.7% of cases), and general discomfort [4]
- Less commonly: nausea/vomiting (3.9%), back pain (1.0%), hypotension (2.4%) [4]
- Timing: typically begins during transfusion or within minutes to hours of starting; severe reactions may present with flushing within 5 minutes followed by temperature spike and rigors ~60 minutes later [5]
- Ask about prior transfusion history and any previous transfusion reactions
- Clarify whether the patient had a pre-existing fever from underlying illness (e.g., infection, malignancy)
- Determine the type of blood product transfused — platelet transfusions carry higher reaction rates [4]
2. Alarm Features
- Temperature rise ≥2°C — raises concern for septic transfusion reaction; must be excluded, especially after platelet transfusion [1]
- Flank/back pain, dark or red urine, hemoglobinuria — classic triad of acute hemolytic transfusion reaction (AHTR) [6]
- Hypotension, tachycardia, shock — consider AHTR, anaphylaxis, or sepsis [1][7]
- Respiratory distress, dyspnea, bilateral infiltrates — consider TRALI or TACO [8]
- Sense of impending doom or severe infusion site pain — highly concerning for AHTR [6]
- DIC, oliguria, or renal failure — suggests AHTR with intravascular hemolysis [7]
- Failure to improve after stopping transfusion and administering antipyretics [1]
3. Medications
- Treatment: Acetaminophen (antipyretics) is the mainstay — used in ~68% of FNHTR cases. Meperidine may be used for severe rigors [1][4]
- Premedication is NOT recommended routinely (Grade 1A) — systematic review and meta-analysis showed no significant reduction in FNHTR with acetaminophen/diphenhydramine premedication (RR 0.54; 95% CI 0.26–1.1) [1][9]
- Premedication may be considered for patients with persistent underlying febrile illness to enable transfusion completion [1]
- Avoid medications that could mask early signs of more serious reactions (e.g., routine corticosteroids are not indicated)
- No contraindicated medications specific to FNHTR, but be cautious with meperidine in renal impairment or patients on MAOIs
4. Diet
- No specific dietary triggers or recommendations
- Ensure adequate hydration, particularly if the patient is febrile
- No acute or long-term dietary management required
5. Review of Systems
- Constitutional: Fever, chills, rigors, malaise
- Respiratory: Dyspnea, cough, shortness of breath (if present, consider TRALI/TACO)
- GI: Nausea, vomiting, abdominal pain (uncommon but reported) [4]
- GU: Urine color changes (dark/red urine → hemolysis), oliguria
- MSK: Back pain, flank pain (→ hemolysis)
- Skin: Rash, urticaria, pruritus (→ allergic reaction rather than FNHTR)
- Cardiovascular: Chest pain, palpitations, edema
6. Collateral History and Family History
- Prior transfusion reactions — patients with a history of FNHTR are at increased risk for recurrence; 42% of patients with prior reactions received premedication before subsequent transfusions [4]
- Transfusion history — number of prior transfusions, prior alloimmunization
- Pregnancy history — multiparous women may have anti-leukocyte antibodies
- Family history is generally not contributory to FNHTR
- Social context: no specific social risk factors
7. Risk Factors
- History of prior transfusion reactions — strongest predictor [10]
- Multi-unit transfusions (≥3 units) — 3.9× greater odds of reaction [10]
- Non-leukoreduced blood products — significantly higher reaction rates [1][5]
- Platelet transfusions — highest reaction rate among all products (821.75 per 100,000 products) [4]
- Stored blood >13 days — 3.85× greater odds of reaction due to cytokine accumulation [10]
- Prior pregnancy or transfusion — increased likelihood of anti-leukocyte antibodies [3]
- Hematologic malignancies/BMT patients — frequently transfused, higher cumulative risk [11]
8. Differential Diagnosis
The critical task is distinguishing FNHTR from dangerous mimics:
- Acute hemolytic transfusion reaction (AHTR) — fever + flank pain + hemoglobinuria; positive DAT; can progress to DIC, renal failure, shock. Fever/chills may be the only early sign in 80% of cases [1][6]
- Septic transfusion reaction — high fever (≥2°C rise), rigors, hypotension; especially after platelet transfusion; Gram stain and culture of product required [1]
- Transfusion-related acute lung injury (TRALI) — fever + acute respiratory distress + bilateral infiltrates within 6 hours; no evidence of volume overload [5]
- Transfusion-associated circulatory overload (TACO) — dyspnea, pulmonary edema, hypertension, elevated BNP; fever present in ~29% of pediatric cases [4]
- Allergic transfusion reaction — urticaria, pruritus, rash; fever uncommon (3.4%) [4]
- Anaphylaxis — hypotension, bronchospasm, angioedema; consider IgA deficiency [3]
- Underlying infection/sepsis — unrelated to transfusion; pre-existing febrile illness
9. Past Medical History
- Prior transfusion reactions (type, severity, management)
- Number of previous transfusions and blood products received
- Hematologic conditions requiring chronic transfusion (sickle cell disease, thalassemia, MDS)
- History of alloimmunization
- Pregnancy history (parity)
- Immunocompromised state (malignancy, chemotherapy, transplant)
- Underlying conditions causing baseline fever (infection, autoimmune disease)
10. Physical Exam
- Vital signs: Temperature (≥1°C rise from baseline), blood pressure (transient hypertension common; hypotension → consider AHTR/sepsis), heart rate, respiratory rate, SpO2
- General: Flushing, diaphoresis, rigors, overall appearance
- Skin: Check for urticaria, rash (→ allergic reaction), jaundice (→ hemolysis), cyanosis
- Lungs: Auscultate for crackles (→ TACO/TRALI), wheezing (→ anaphylaxis)
- Cardiovascular: JVD, S3 gallop (→ volume overload)
- Abdomen: Flank tenderness (→ hemolysis with renal capsular distension)
- IV site: Inspect for pain, erythema, or signs of infiltration
- Urine: Visual inspection for dark/red color (hemoglobinuria)
11. Lab Studies
FNHTR is a diagnosis of exclusion. The following labs rule out dangerous alternatives:
- Direct antiglobulin test (DAT/direct Coombs) — must be negative to exclude immune-mediated hemolysis [1][6]
- Visual inspection of post-transfusion plasma — check for hemolysis (pink/red discoloration) [1]
- Repeat ABO/Rh typing and crossmatch — to exclude clerical error [1]
- CBC — evaluate for hemoglobin drop
- LDH, haptoglobin, indirect bilirubin — hemolysis markers [7]
- Blood cultures (patient and product) — if septic reaction suspected, especially with ≥2°C rise or after platelet transfusion [1]
- Gram stain of residual product — if bacterial contamination suspected
- Urinalysis — hemoglobinuria
- BNP/NT-proBNP — if TACO is a concern
12. Imaging
- Chest X-ray — indicated only if respiratory symptoms are present to evaluate for TRALI (bilateral infiltrates without cardiomegaly) or TACO (pulmonary edema with vascular congestion) [5]
- Imaging is not routinely necessary for isolated FNHTR without respiratory or hemodynamic compromise
- No gold standard imaging for FNHTR itself
13. Special Tests
- Clerical check — verify patient identification and product labeling match at bedside (universal first step) [1]
- Transfusion reaction workup — standardized institutional protocol including DAT, visual hemolysis check, repeat type and screen
- No validated scoring system specific to FNHTR
- Point-of-care temperature monitoring is essential during all transfusions
14. ECG
- Not routinely indicated for isolated FNHTR
- Obtain ECG if hemodynamic instability, chest pain, or arrhythmia is present
- Consider ECG in patients with underlying cardiac disease receiving transfusions
- No specific ECG pattern associated with FNHTR
15. Assessment
FNHTR is a benign, self-limited reaction that is the most common adverse transfusion event. [1-2] It presents with fever (≥1°C rise), chills, and rigors during or shortly after transfusion. The critical clinical challenge is that fever and chills may be the only early signs of AHTR (present in 80% of cases), making FNHTR a diagnosis of exclusion that requires a systematic workup to rule out hemolysis and sepsis before the diagnosis can be confirmed. [1]
Severity stratification:
- Mild: Temperature rise 1–2°C, chills, responds to antipyretics
- Moderate: Rigors, significant discomfort, slow to respond
- Severe/Atypical: Temperature rise ≥2°C, hypotension, back pain, respiratory symptoms → must aggressively exclude AHTR, sepsis, TRALI
16. Treatment Plan
Immediate management
- Stop the transfusion immediately [1]
- Keep IV line open with normal saline [1]
- Verify patient identification and product labeling — clerical check [1]
- Send transfusion reaction workup — DAT, visual hemolysis check, repeat type and crossmatch, blood cultures if indicated
- Administer acetaminophen 650–1000 mg PO/PR for fever [1][4]
- Meperidine 25–50 mg IV for severe rigors [1]
- Provide supportive care and monitor vital signs closely
After workup returns negative for hemolysis/sepsis
- The transfusion may be resumed with a new unit if clinically indicated, though the implicated unit should not be restarted
- Report the reaction to the blood bank/transfusion medicine service and institutional hemovigilance system [8]
Prevention for future transfusions
- Pre-storage leukoreduction is the most effective prevention strategy (Grade 1A) [1][3]
- Platelet additive solutions reduce FNHTR rates from 0.5% to 0.17% (Grade 1B) [1]
- Routine premedication with acetaminophen/diphenhydramine is not recommended (Grade 1A) — meta-analysis of 3 RCTs (517 patients, 4444 transfusions) showed no significant benefit (RR 0.92; 95% CI 0.63–1.35) [1][9][12]
- For patients with recurrent FNHTR, consider leukoreduced products, washed products, or volume-reduced products [2]
17. Disposition
- Discharge criteria: Symptoms resolve with antipyretics, vital signs normalize, transfusion reaction workup negative for hemolysis and sepsis, no respiratory compromise
- Observation: Patients who are slow to respond or have atypical features should be observed until workup results return and symptoms fully resolve
- Admission criteria: Hemodynamic instability, respiratory distress, positive hemolysis workup, suspected septic reaction, or failure to improve
- Specialist consultation: Transfusion medicine/blood bank should be notified for all reactions; hematology consultation if recurrent reactions or complex transfusion needs
18. Follow Up / Return Precautions
- Document the reaction in the medical record and blood bank system for future transfusion planning [8]
- Patients with recurrent FNHTR should receive leukoreduced products for all future transfusions [1]
- Return precautions: Instruct patients to report fever, chills, dark urine, back pain, shortness of breath, or rash with any future transfusion
- Expected course: symptoms typically resolve within 1–2 hours of stopping the transfusion and administering antipyretics
- Follow-up with primary team or hematology if recurrent reactions occur to discuss modified blood product strategies (washed, volume-reduced, or irradiated products)
Images
References
1. Transfusion Reactions: Prevention, Diagnosis, and Treatment. — Delaney M, Wendel S, Bercovitz RS, et al. Lancet. 2016.
2. Noninfectious Transfusion-Associated Adverse Events and Their Mitigation Strategies. — Goel R, Tobian AAR, Shaz BH. Blood. 2019.
3. Immunological Complications of Blood Transfusion: Current Insights and Advances. — Bansal N, Raturi M, Singh C, Bansal Y. Current Opinion in Immunology. 2025.
4. Epidemiology of Pediatric Transfusion Reactions. — Stone EF, Chacreton D, Jimenez A, et al. JAMA Network Open. 2026.
5. Red Blood Cell Transfusion in Clinical Practice. — Klein HG, Spahn DR, Carson JL. Lancet. 2007.
6. Hemolytic Transfusion Reactions. — Panch SR, Montemayor-Garcia C, Klein HG. The New England Journal of Medicine. 2019.
7. Hematologic Emergencies: Recognition and Initial Management. — Jones DE, Walker JJ, Abellada AMP. American Family Physician. 2024.
8. Blood Transfusion Reactions-a Comprehensive Review of the Literature Including a Swiss Perspective. — Ackfeld T, Schmutz T, Guechi Y, Le Terrier C. Journal of Clinical Medicine. 2022.
9. Premedication for the Prevention of Nonhemolytic Transfusion Reactions: A Systematic Review and Meta-Analysis. — Ning S, Solh Z, Arnold DM, Morin PA. Transfusion. 2019.
10. Incidence of Acute Transfusion Reactions and Associated Factors Among Adult Blood-Transfused Patients at Jimma University Medical Center, Southwest Ethiopia: A Cross-Sectional Study. — Tadasa E, Adissu W, Bekele M, Arega G, Gedefaw L. Medicine. 2024.
11. A Prospective, Randomized, Double-Blind Controlled Trial of Acetaminophen and Diphenhydramine Pretransfusion Medication Versus Placebo for the Prevention of Transfusion Reactions. — Kennedy LD, Case LD, Hurd DD, Cruz JM, Pomper GJ. Transfusion. 2008.
12. Pharmacological Interventions for the Prevention of Allergic and Febrile Non-Haemolytic Transfusion Reactions. — Martí-Carvajal AJ, Solà I, González LE, Leon de Gonzalez G, Rodriguez-Malagon N. The Cochrane Database of Systematic Reviews. 2010.